Myelofibrosis Clinical Trials in Durham, North Carolina

5 studies are recruiting for myelofibrosis in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

   The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness,…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke Blood Cancer Center, Durham, North Carolina

   Locations

   195 in total

   Run by

   Takeda

   See if you can join NCT07623161 on ClinicalTrials.gov

2. A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

   This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   90 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04176198 on ClinicalTrials.gov

3. A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

   The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   DUHS Duke Blood Cancer Center ( Site 6005), Durham, North Carolina

   Locations

   21 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06351631 on ClinicalTrials.gov

4. A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

   The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assesse…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   70 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT05980806 on ClinicalTrials.gov

5. Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

   This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in t…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   215 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT06479135 on ClinicalTrials.gov